Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs). After: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs).
Planned enrollment increased by 160 participants
Before: 80 participants (planned). After: 240 participants (planned).
Primary completion date changed
Before: Nov 2028. After: May 2030.